JPS5913721A - Agent for suppressing formation of bacterial plaque on tooth - Google Patents

Agent for suppressing formation of bacterial plaque on tooth

Info

Publication number
JPS5913721A
JPS5913721A JP57123260A JP12326082A JPS5913721A JP S5913721 A JPS5913721 A JP S5913721A JP 57123260 A JP57123260 A JP 57123260A JP 12326082 A JP12326082 A JP 12326082A JP S5913721 A JPS5913721 A JP S5913721A
Authority
JP
Japan
Prior art keywords
agent
flavonoid
adhesion
activity
oral cavity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57123260A
Other languages
Japanese (ja)
Other versions
JPS6310133B2 (en
Inventor
Tsuneo Nanba
難波 恒雄
Yukio Hattori
征雄 服部
Masago Kyozuka
経塚 真砂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TSURUI YAKUHIN KOGYO KK
Original Assignee
TSURUI YAKUHIN KOGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TSURUI YAKUHIN KOGYO KK filed Critical TSURUI YAKUHIN KOGYO KK
Priority to JP57123260A priority Critical patent/JPS5913721A/en
Publication of JPS5913721A publication Critical patent/JPS5913721A/en
Publication of JPS6310133B2 publication Critical patent/JPS6310133B2/ja
Granted legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

PURPOSE:To provide an agent for oral cavity application, containing flavonoid as an active component, suppressing the adhesion of cariogenic bacteria to the flat surface of the teeth, and effective to prevent or inhibit the progress of dental caries. CONSTITUTION:Flavonoid such as rhamnocitrin, kaempferol, etc. is used as a pure substance, or in the form of a vegetable extract containing the same, if necessary in combination with other plaque-formation inhibiting agent or conventional agent for oral cavity application. Flavonoid exhibits the activity to suppress the adhesion of Streptococcus mutans to flat glass surface by in vitro test, and the inhibiting activity to the synthesis of glucan from sucrose by crude glucosyltransferase originated from Streptococcus mutans.

Description

【発明の詳細な説明】 本発明は歯石形成抑制剤に関するもので、さらに具体的
には特許請求の範囲に記載のように、フラボノイドから
成る歯石形成抑制剤に関1−るものであって、その目的
とするところは歯面圧おける歯石の形成を抑制E7、以
って鈷蝕を予防し又はその進行を阻止するために有効な
口腔用剤を提供することにある。
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a dental calculus formation inhibitor, and more specifically, as described in the claims, relates to a dental calculus formation inhibitor comprising flavonoids, The purpose is to provide an oral agent that is effective in inhibiting the formation of tartar on tooth surface pressure, thereby preventing erosion or inhibiting its progression.

酬蝕けふつう1むしば」と呼ばれ、歯が限局性かつ進行
性に公 破壊される疾患であって、そのM思率は極めて萬く現在
の衆衛生上の重要問題と々っている。
It is a disease that causes localized and progressive destruction of the teeth, and is considered an extremely serious problem in current public health. .

この順テ・I+という現象は、口腔連鎖球菌なかんづく
5treptorhccue mutannが食物中の
シュークロースを基質として、粘着性の多糖体Cグルカ
ン)を生成し、このグルカンによって菌体が歯の平滑面
に付着し定着することからその第一歩が始まるものであ
る。
This phenomenon is caused by the fact that oral streptococci, especially Streptococcus mutan, use sucrose in food as a substrate to produce a sticky polysaccharide (C-glucan), which allows the bacterial cells to adhere to the smooth surfaces of teeth. The first step is to take root.

南面に凝集し定着するこの菌体の集合体を歯石(Plp
−que 1 と称する。そ]、て鯖蝕防止のためには
上記の歯石形成を抑制すれは良いわけである。このよう
な歯石の形成を抑制するには次のようないろいろな方法
が考えられる。
This aggregate of bacteria that aggregates and colonizes on the south side is called dental calculus (Plp).
−que 1 . In order to prevent dental caries, it is good to suppress the formation of tartar mentioned above. The following various methods can be considered to suppress the formation of such tartar.

まず考えられるのは、8.mutan日に対して殺菌又
l−を静菌作用を示す薬物を投与し、口腔内から昭蝕原
性Me駆逐する方法であり、実際にもある稈度試みられ
てい乙。しかしこれらの薬物は口腔内及び腸内の細菌叢
を攪乱し自財界の細菌のバランスを崩したりその他の副
作用を随伴する危険があって、ひろく用いられるには致
ってい々い。
The first thing that comes to mind is 8. This method involves administering a drug that exhibits bactericidal or bacteriostatic activity to eradicating cariogenic Me from the oral cavity, and this method has actually been attempted in some cases. However, these drugs have the risk of disturbing the bacterial flora in the oral cavity and intestines, causing an imbalance of bacteria in the natural world, and are accompanied by other side effects, so they are far from being widely used.

次ICは祷械的方法で歯石をとり除く方法があり、日常
的にはハブテンを用いて行っているものであるが、これ
は手を用いての物理的清掃であって、完全((歯石を除
去することは困難である0 本発明者らは、歯石形成の適確々抑制方法について種々
の研究を重ね、剛蝕原性菌の歯の平滑面への付着を阻止
する手段についてひろく検討を行ったところ、まったく
予想し方かったことであるが、フラボノイドがそのよう
な作用を有することを見出し、さらVc深く研究の結果
、ついに本発明を完成したものである。以下に本発明の
効果を示す実験方法とその結果について詳細に説明する
Next, there is a mechanical method for removing tartar from IC, and it is routinely done using Habten, but this is a physical cleaning using the hands and does not completely remove tartar ((tartar). It is difficult to remove the tartar.0 The present inventors have conducted various studies on methods for appropriately and accurately inhibiting the formation of tartar, and have extensively examined means for preventing the adhesion of caryogenic bacteria to the smooth surfaces of teeth. As a result of their research, they discovered that flavonoids had such an effect, which was completely unexpected, and as a result of further deep research into Vc, they finally completed the present invention.The following describes the effects of the present invention. The experimental method and results will be explained in detail.

−J−t7、S 、 mutFLnsの平滑面付着に対
してフラボノイドの示す抑制活性の検定は、次の2点に
ついて行った8なおこれらはい41/ ず〜もin vitroのテストである。
The inhibitory activity of flavonoids against the smooth surface adhesion of -J-t7, S, mutFLns was assayed for the following two points.8 These are also in vitro tests.

(1)  シュークロースの存在下、S、mutans
加熱処理菌体のR、mutanθ由来粗グルコシルトラ
ンスフェラーゼによるガラス平滑面付着に対する明IJ
−9作用f21  S 、mu tanq 由来粗グル
コシルトランスフェラーゼによる次にそれぞれについて
、さらに詳細に説明する。
(1) In the presence of sucrose, S. mutans
Akira IJ on glass smooth surface adhesion by R, mutanθ-derived crude glucosyltransferase of heat-treated bacterial cells
-9 action by f21 S , mutanq-derived crude glucosyltransferase Next, each will be explained in more detail.

寸ず(1)の菌体付着目1止作用から述べる。検定の方
法は本出願人の既出願(特願昭56−156963)に
おいて述べた方法に準じ、オたs 、mute、ns加
熱処理死菌及び粗グルコシルトランスフェラーゼについ
ても、S、mutan日OMZ+76株を用い既出願に
おけると同様fして調製し、た。寸たフラボノイドト↑
メタノールに溶解して被験液とした。ただし付着阻止活
性の判定は、インキュベートの終了後に浮遊菌体音除去
して付着菌体を3Mlのffl製氷に浮遊さ拷、その5
50nm+VCおける濁度を測定しこ凡を付着菌体仔と
1〜で、溶媒のみ添加の対照のそれと比較すること1C
より付着1壜11.活性を求めた。その結果を第1fi
[示す。
The effect of Zuzu (1) on preventing bacterial cell adhesion will be explained first. The assay method was similar to the method described in the applicant's previous application (Japanese Patent Application No. 156,963/1983), and for the heat-killed bacteria and crude glucosyltransferase, S, mutan, and OMZ+76 strains were used. It was prepared in the same manner as in the previous application. Flavonoids ↑
It was dissolved in methanol to prepare a test solution. However, to judge the adhesion inhibition activity, after the incubation is completed, the airborne bacterial bodies are removed and the adhered bacterial bodies are suspended in 3 ml of FFL ice.
Measure the turbidity at 50 nm + VC and compare it with that of a control with only solvent added at 1C with attached bacterial cells.
1 bottle 11. Activity was determined. The result is the first fi.
[show.

第1表t(示十よう(で、本発明によるフラボノイ1′
、特にケンフェロール、ケルセチン、及びミリセチンは
すぐれた付着阻止活性を示す。
Table 1 shows the flavonoids according to the present invention.
In particular, kaempferol, quercetin, and myricetin exhibit excellent antiadhesion activity.

次に(2)のグルカン合成阻害活性に一ついて述べろ。Next, explain the glucan synthesis inhibitory activity in (2).

グルカン合成とその定量は次のようにして行ったC、ま
す゛、005Mリン酸緩衝液(pl+68、以後P、B
、と略す)350μe、1.R%シュークロース含有P
、B、200/I/?、及び被験液30μeをよく混合
し、氷水中にて冷却しつつグルコシルトランスフェラー
ゼ(75■覧白/m1)20μeを加え、よく混合して
37°Cjτて2時間・インキュベートする。インギュ
ベート終了後直ちに氷水中も・γとり、冷メタノール2
.4 II+7を加クーて攪拌後、5°Cにて1晩放置
する。
Glucan synthesis and its quantification were carried out as follows.
, abbreviated as) 350 μe, 1. R% sucrose containing P
, B, 200/I/? , and 30 μe of the test solution were mixed well, and while cooling in ice water, 20 μe of glucosyltransferase (75 μm/ml) was added, mixed well, and incubated at 37°C for 2 hours. Immediately after incubation, remove γ in ice water and add cold methanol 2.
.. 4 Add II+7 and stir, then leave at 5°C overnight.

へ− Blankは同様の反応でインキュートしないものとす
る。冷却して十分にグルカンをメタノール沈澱させた後
、遠心(20ρ00g、20分、5°C)Kて残渣をと
り、これを冷80悸メタノール2mlで2回洗浄l−で
生成グルカンを得る。これを1. N NFLOH50
0treKて溶解し生成グルカン溶液とする。この糖量
をPhen91− Ht 130・法にて定量する。す
kわち、生成グルカン溶液500tteVC対17.5
チphen01水溶液500μeを加えて混合さらに濃
+1y 80m 2.5117を直接液面に速やかに加
えて十分に攪拌後、10分間室温にて放置した後、さら
に27°CVCて20分間保ち発色を完了させる。49
0 nr+t17おける吸光度を測定し7、シュークロ
ースを標準物質として糖量に換算した。発色に及ぼすエ
キスの影響等は同一反応系でインキュベートし々いもの
をBlankとしてとり考慮した。対照は溶媒メタノー
ル(配糖体は精製水)のみを添加したものとし斤。
-Blank shall not be incubated in the same reaction. After cooling and sufficiently precipitating the glucan with methanol, centrifugation (20p00g, 20 minutes, 5°C) is performed to collect the residue, which is washed twice with 2ml of cold methanol at 80°C to obtain the produced glucan. This is 1. N NFLOH50
Dissolve at 0 treK to obtain a produced glucan solution. The amount of sugar is determined by the Phen91-Ht130 method. That is, the produced glucan solution 500tte VC vs. 17.5
Add 500μe of Typhen01 aqueous solution and mix.Concentrate +1y 80m 2.5117 is quickly added directly to the liquid surface, stirred thoroughly, left at room temperature for 10 minutes, and then kept at 27°CVC for another 20 minutes to complete color development. . 49
The absorbance at 0 nr+t17 was measured 7 and converted into sugar content using sucrose as a standard substance. The influence of the extract on color development, etc. was taken into consideration by using the sample that had been incubated in the same reaction system for a while as a blank. The control was a loaf in which only the solvent methanol (purified water for the glycoside) was added.

第   2   表 tJt2表に示すように、本発明によるフラボノイド、
特にラムノシトリン及びケンフェロールは強力な阻害活
性を示し、これは従来顕著なグルカン合成阻害活性の報
告されているクロルヘキシジングルコネートにも勝るも
のである。
As shown in Table 2, flavonoids according to the present invention,
In particular, rhamnocitrin and kaempferol exhibit strong inhibitory activity, which is superior to chlorhexidine gluconate, which has been reported to have significant glucan synthesis inhibitory activity.

本発明において使用されるフラボノイドは、−名フラボ
ン系色素又はアントキザンチン々どとも称されていたも
ので、種々のフラボン類、フラボノール類、イソフラボ
ン類、フラバノン類、フラバノノール類、カルコン類、
ペンザルクララノン類、アンドンアン類等を包合するも
のである。これらのフラボノイドは単独に用いても良い
し、界なったものを混合しても良い。
The flavonoids used in the present invention are also called flavonoid pigments or anthoxanthins, and include various flavones, flavonols, isoflavones, flavanones, flavanonols, chalcones,
It encompasses penzalkuraranones, andonanes, etc. These flavonoids may be used alone or in combination.

iた純品でも良いし、さらにはこれらフラボノイドを含
有する植物エキスの形態であっても良い。たとえば@I
のメタノール抽出液は高単位のラムノシ) IJンを含
有するため、そのメタノールエキスを用いるが如きはそ
の一例である。必要に応じこれらのものに、さらに他の
歯石形成抑制剤や一般の口腔用剤、さらvcV!iS 
、mutane Ic対し殺菌又は静菌作用を示す薬物
を併用しても良い。
It may be a pure product, or it may be in the form of a plant extract containing these flavonoids. For example @I
An example of this is the use of a methanol extract, which contains a high amount of rhamnosium IJ. If necessary, in addition to these, other tartar formation inhibitors, general oral preparations, and even VCV! iS
, a drug that exhibits bactericidal or bacteriostatic activity against mutane Ic may be used in combination.

本発明による歯石形成抑制剤はこれをそのitの形態で
直接に口腔内圧適用しても良いし、他の口腔剤たとえば
歯磨と混合したり、さらには口腔内スプレー剤や含、・
軟剤の形態で用いても良い。必要に応じトローチ、舌下
錠、バッカル剤、チューイング剤その他の剤型でも良い
The tartar formation inhibitor according to the present invention may be applied directly to intraoral pressure in its form, or may be mixed with other oral preparations such as toothpaste, or may be used as an intraoral spray.
It may also be used in the form of a softener. Troches, sublingual tablets, buccal tablets, chewing tablets, and other dosage forms may be used as required.

用量としては上述の実験データから考えられるところの
適当な眼を用いるのが良いが、使用中の損失たとえば歯
磨に混じた時々どけかなりの量が口すすぎによ松流失す
ることを考慮し、多少の又はか寿りの過剰量を用いるこ
とが望オしい。
It is best to use an appropriate dose based on the above experimental data, but considering the loss during use, for example, a considerable amount may be washed away when rinsing the mouth when mixed with toothpaste, It is advisable to use an excess amount of water.

以上that's all

Claims (1)

【特許請求の範囲】[Claims] 1 フラボノイドから成る歯石形成抑制剤1 Tartar formation inhibitor consisting of flavonoids
JP57123260A 1982-07-15 1982-07-15 Agent for suppressing formation of bacterial plaque on tooth Granted JPS5913721A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP57123260A JPS5913721A (en) 1982-07-15 1982-07-15 Agent for suppressing formation of bacterial plaque on tooth

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57123260A JPS5913721A (en) 1982-07-15 1982-07-15 Agent for suppressing formation of bacterial plaque on tooth

Publications (2)

Publication Number Publication Date
JPS5913721A true JPS5913721A (en) 1984-01-24
JPS6310133B2 JPS6310133B2 (en) 1988-03-04

Family

ID=14856156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57123260A Granted JPS5913721A (en) 1982-07-15 1982-07-15 Agent for suppressing formation of bacterial plaque on tooth

Country Status (1)

Country Link
JP (1) JPS5913721A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230702A (en) * 1990-04-12 1992-08-19 Mckinley Opt Inc Endoscope relay lens
KR100368007B1 (en) * 2000-04-17 2003-01-24 국보제약주식회사 Oral composition containing minocycline HCL
JP2003081847A (en) * 2001-09-12 2003-03-19 Maruzen Pharmaceut Co Ltd Odontonecrosis-preventing agent and oral composition
KR100417259B1 (en) * 2000-04-17 2004-02-05 국보제약주식회사 Oral composition containing triamcinolone acetonide
KR100417261B1 (en) * 2000-04-17 2004-02-05 국보제약주식회사 Oral composition containing bacteriocin
KR100417260B1 (en) * 2000-04-17 2004-02-05 국보제약주식회사 Oral composition containing titrated extract of the unsaponifiable fraction of zea mays
JP4585066B2 (en) * 1999-10-19 2010-11-24 丸善製薬株式会社 Caries inhibitor, oral preparation and food and drink
CN102464641A (en) * 2010-11-19 2012-05-23 苏州宝泽堂医药科技有限公司 Method for preparing rhamnus limonin from oxytropis falcate
CN102652712A (en) * 2011-03-04 2012-09-05 全球生技股份有限公司 Antibacterial oral care composition and preparation method thereof
KR20160059605A (en) * 2014-11-19 2016-05-27 대한민국(환경부 국립생물자원관장) Composition for preventing or treating cavity and periodontal disease comprising kaempferol as effective component

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58213706A (en) * 1982-06-08 1983-12-12 Lion Corp Composition for oral cavity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58213706A (en) * 1982-06-08 1983-12-12 Lion Corp Composition for oral cavity

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04230702A (en) * 1990-04-12 1992-08-19 Mckinley Opt Inc Endoscope relay lens
JP4585066B2 (en) * 1999-10-19 2010-11-24 丸善製薬株式会社 Caries inhibitor, oral preparation and food and drink
KR100368007B1 (en) * 2000-04-17 2003-01-24 국보제약주식회사 Oral composition containing minocycline HCL
KR100417259B1 (en) * 2000-04-17 2004-02-05 국보제약주식회사 Oral composition containing triamcinolone acetonide
KR100417261B1 (en) * 2000-04-17 2004-02-05 국보제약주식회사 Oral composition containing bacteriocin
KR100417260B1 (en) * 2000-04-17 2004-02-05 국보제약주식회사 Oral composition containing titrated extract of the unsaponifiable fraction of zea mays
JP2003081847A (en) * 2001-09-12 2003-03-19 Maruzen Pharmaceut Co Ltd Odontonecrosis-preventing agent and oral composition
CN102464641A (en) * 2010-11-19 2012-05-23 苏州宝泽堂医药科技有限公司 Method for preparing rhamnus limonin from oxytropis falcate
CN102652712A (en) * 2011-03-04 2012-09-05 全球生技股份有限公司 Antibacterial oral care composition and preparation method thereof
KR20160059605A (en) * 2014-11-19 2016-05-27 대한민국(환경부 국립생물자원관장) Composition for preventing or treating cavity and periodontal disease comprising kaempferol as effective component

Also Published As

Publication number Publication date
JPS6310133B2 (en) 1988-03-04

Similar Documents

Publication Publication Date Title
US20040057908A1 (en) Oral compositions and use thereof
JPH01308219A (en) Oral cavity composition
EP1399119A2 (en) Oral compositions and use thereof
JPS5913721A (en) Agent for suppressing formation of bacterial plaque on tooth
JPS6326083B2 (en)
JP4852223B2 (en) Coaggregation inhibitor of oral bacteria
US4963346A (en) Method and composition for treatment or prevention of dental plaque calculus and gingivitis
JP3837172B2 (en) Inhibitor of adhesion to periodontal tissue of Porphyromonas gingivalis containing high molecular weight polyphenol as an active ingredient
JP3013060B2 (en) Oral composition for inhibiting and detaching tooth decay from tooth decay
JPS5811924B2 (en) Oral composition
JP2000502069A (en) Oral pharmaceutical composition containing NSAID and ceramide
JPS59152311A (en) Oral cavity composition
CN101011336A (en) Use of bamboo leaf flavone in preparation of oral cavity cleaning and nursing product
JPS5811927B2 (en) Oral composition
JP2000191487A (en) Oral cavity agent composition and food and drink composition for inhibiting matrix metalloprotease
JP2999791B2 (en) Method for enhancing glucosyltransferase inhibitory activity
JPH0717839A (en) Composition for oral cavity application
JP4633399B2 (en) Glucosyltransferase inhibitor
JPH07242555A (en) Glucosyl transferase-inhibiting agent and dental caries-resistant agent and dental caries-resistant food containing the same as active ingredient
JPH01290619A (en) Production of composition for oral cavity
JPS6045512A (en) Caries inhibitor
JP3319748B2 (en) Caries inhibitor
JP2859612B1 (en) Caries prevention agent
JP2833041B2 (en) Oral composition
JPH0466524A (en) Composition for use in oral cavity